Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash from Financing Activities (2019 - 2025)

Historic Cash from Financing Activities for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $4.8 million.

  • Biodesix's Cash from Financing Activities rose 324861.11% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year decrease of 8035.8%. This contributed to the annual value of $52.0 million for FY2024, which is 7868.79% up from last year.
  • Biodesix's Cash from Financing Activities amounted to $4.8 million in Q3 2025, which was up 324861.11% from $9.8 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Cash from Financing Activities peaked at $51.3 million during Q2 2024, and registered a low of -$4.4 million during Q4 2021.
  • For the 5-year period, Biodesix's Cash from Financing Activities averaged around $8.2 million, with its median value being $396000.0 (2021).
  • Data for Biodesix's Cash from Financing Activities shows a peak YoY increase of 786151.08% (in 2022) and a maximum YoY decrease of 67196.97% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Biodesix's Cash from Financing Activities stood at -$4.4 million in 2021, then skyrocketed by 1059.16% to $41.8 million in 2022, then crashed by 48.08% to $21.7 million in 2023, then tumbled by 100.83% to -$181000.0 in 2024, then soared by 2764.09% to $4.8 million in 2025.
  • Its Cash from Financing Activities was $4.8 million in Q3 2025, compared to $9.8 million in Q2 2025 and $97000.0 in Q1 2025.